BioSpace News Archive

Biogen Inc. announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023.

In the United States alone, drug-resistant bacteria and fungi infect almost 3 million people per year and kill about 35,000.

Lokavant, the clinical trial intelligence platform company, has achieved significant business milestones within three months of the company’s $21 million Series A funding announcement

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a global leader in nanomedicines against viruses, announced today that it has executed a License Agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India (“Karveer”).

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced its full year 2022 financial results and provided strategic updates on its clinical programs.

electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase by clinicians through the Carrick Institute for Graduate Studies which provides clinical neuroscience education.

Addex Therapeutics announced data showing that dipraglurant could have beneficial effects on non-motor symptoms experienced by Parkinson’s patients in addition to its established positive effects on dyskinesias.

Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc., the Korean drug development company, announced that they have mutually agreed to terminate their collaboration and licensing agreement.

Medivir AB announces that the Annual Report for 2022 now is available at the company’s website.

Cingulate Inc. announced it has completed the first cohort of its Phase 3 adult onset and duration trial of its lead candidate, CTx-1301, for attention deficit/hyperactivity disorder.